---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-014909"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T08:09:55.992993+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Genprex enters new sponsored research agreement with University of Pittsburgh for GPX-002 diabetes gene therapy

## Summary
- New SRA with Pitt for preclinical studies of GPX-002 in T1D and T2D animal models.
- Preclinical T1D data showed statistically significant decreases in insulin requirements and increases in c-peptide levels.
- GPX-002 uses adeno-associated virus vector with Pdx1 and MafA genes delivered via pancreatic duct.
- In T1D, GPX-002 aims to transform alpha cells into functional beta-like cells to evade immune system.
- In T2D, GPX-002 is believed to rejuvenate exhausted beta cells.

## SEC filing metadata
- accession: 0001437749-25-014909
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774925014909/0001437749-25-014909-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774925014909/gnpx20250506_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-014909
- JSON: https://secwatch.observer/filing/0001437749-25-014909.json
- Plain text: https://secwatch.observer/filing/0001437749-25-014909.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.